Fenofibrate modulates HO-1 and ameliorates endothelial expression of cell adhesion molecules in systolic heart failure

Acta Cardiologica Sinica

Volumn 29, Issue 3, 2013, Pages 251-260

  Yin, Wei Hsian ^a,b   Chen, Jaw Wen ^c,d   Chen, Yung Hsiang ^e   Lin, Shing Jong ^b,c  

^a CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d Institute of Pharmacology   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cell adhesion molecules; Endothelial cells; Heart failure; Heme oxygenase 1; Peroxisome proliferator activated receptor

Indexed keywords

CELL ADHESION MOLECULE; FENOFIBRATE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTOPORPHYRIN COBALT; SMALL INTERFERING RNA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL ACTIVATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PULMONARY ARTERY; SYSTOLIC HEART FAILURE; UPREGULATION; WESTERN BLOTTING;

EID: 84878323367     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Wrigley BJ, Lip GY, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail 2011;13: 1161-71.
2. Chong AY, Blann AD, Patel J, et al. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 2004; 110: 1794-8.
3. Chong AY, Freestone B, Patel J, et al. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 2006; 97: 671-5.
4. Verma A, Bulwer B, Dhawan I, et al. Aldosterone receptor antagonist and heart failure following acute myocardial infarction. Acta Cardiol Sin 2010;26: 203-15.
5. Chen CN, Chen HR, Chang HI, et al. Relationship between the antiplatelet effect of aspirin and serum VCAM-1 concentration in patients at high risk for cardiovascular events. Acta Cardiol Sin 2010;26: 28-36.
6. Tsutamoto T, Hisanaga T, Fukai D, et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin- 1 concentration in patients with chronic congestive heart failure. Am J Cardiol 1995;76: 803-8.
7. Tousoulis D, Homaei H, Ahmed N, et al. Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy. Am Heart J 2001;141: 277-80.
8. Yin WH, Chen JW, Jen HL, et al. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail 2003;5: 507-16.
9. Geppert A, Zorn G, Heinz G, et al. Soluble selectins in the pulmonary and systemic circulation in acute cardiogenic and noncardiogenic pulmonary failure. Intensive Care Med 2001;27: 521-7.
10. Yin WH, Jen HL, Chiang MC, et al. Circulating soluble tumor necrosis factor-?and cell adhesion molecules in patients with acute cardiogenic pulmonary edema. J Emerg Crit Care Med 2004;15: 9-19.
11. Yin WH, Chen JW, Young MS, Lin SJ. Increased endothelial monocyte adhesiveness is related to clinical outcomes in chronic heart failure. Int J Cardiol 2007;121: 276-83.
12. Lakkisto P, Kytö V, Forsten H, et al. Heme oxygenase-1 and carbon monoxide promote neovascularization after myocardial infarction by modulating the expression of HIF-1alpha, SDF-1alpha and VEGF-B. Eur J Pharmacol 2010;635: 156-64.
13. Wang G, Hamid T, Keith RJ, et al. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation 2010;121: 1912-25.
14. Tang JM, Wang JN, Zhang L, et al. VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Res 2011;91: 402-11.
15. Lakkisto P, Siren JM, Kytö V, et al. Heme oxygenase-1 induction protects the heart and modulates cellular and extracellular remodeling after myocardial infarction in rats. Exp Biol Med (Maywood) 2011;236: 1437-48.
16. Wu ML, Ho YC, Yet SF. A central role of heme oxygenase-1 in cardiovascular protection. Antioxid Redox Signal 2011;15: 1835-46.
17. Lam CF, Croatt AJ, Richardson DM, et al. Heart failure increases protein expression and enzyme activity of heme oxygenase-1 in the lung. Cardiovasc Res 2005;65: 203-10.
18. Soares MP, Seldon MP, Gregoire IP, et al. Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. J Immunol 2004;172: 3553-63.
19. Brouard S, Otterbein LE, Anrather J, et al. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 2000;192: 1015-26.
20. Luptak I, Balschi JA, Xing Y, et al. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptoralpha- null hearts can be rescued by increasing glucose transport and utilization. Circulation 2005;112: 2339-46.
21. Labinskyy V, Bellomo M, Chandler MP, et al. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure. J Pharmacol Exp Ther 2007;321: 165-71.
22. Sweets PJ, Teunissen BE, Willemsen PH, et al. Cardiac hypertrophy is enhanced in PPAR alpha -/- mice in response to chronic pressure overload. Cardiovasc Res 2008;78: 79-89.
23. Balakumar P, Rohilla A, Mahadevan N. Pleiotropic actions of fenofibrate on the heart. Pharmacol Res 2011;63: 8-12.
24. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 2005;288:H1037-43.
25. Sweets PJ, de Vogel-van den Bosch HM, Willemsen PH, et al. Transcriptomic analysis of PPARalpha-dependent alterations during cardiac hypertrophy. Physiol Genomics 2008;36: 15-23.
26. Ogata T, Miyauchi T, Sakai S, et al. Stimulation of peroxisomeproliferator- activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond) 2002;103:284S-8S.
27. Ogata T, Miyauchi T, Sakai S, et al. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factorkappa- B pathway. J Am Coll Cardiol 2004;43: 1481-8.
28. Diep QN, Benkirane K, Amiri F, et al. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 2004;36: 295-304.
29. Ichihara S, Obata K, Yamada Y, et al. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 2006;41: 318-29.
30. Wayman NS, Hattori Y, McDonald MC, et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002;16: 1027-40.
31. Huang WP, Yin WH, Chen JW, et al. Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study. Eur J Clin Invest 2009;39: 775-83.
32. Lavrovsky Y, Schwartzman ML, Levere RD, et al. Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci U S A 1994;91: 5987-91.
33. Krönke G, Kadl A, Ikonomu E, et al. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 2007;27: 1276-82.
34. Oikonomou E, Tousoulis D, Siasos G, et al. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol 2011;52: 30-40.
35. Picano E, Morales MA, del Ry S, Sicari R. Innate inflammation in myocardial perfusion and its implication for heart failure. Ann N Y Acad Sci 2010;1207: 107-15.
36. Chen YH, Lin SJ, Lin MW, et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002;111: 1-8.
37. Chen YH, Chau LY, Lin MW, et al. Heme oxygenase-1 gene promotor microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J 2004; 25: 39-47.
38. Balfour JA, McTavish D, Heel RC. Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990;40: 260-90.